1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Rest Ez Inc.

Rest Ez Inc.

RTEZ
Rest Ez Inc.US flagOther OTC
70.00
USD
- -
- -
1.93BMarket Cap
Rest Ez Inc.
RTEZ
(Other OTC)

Recent

price

70.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
5.25
25.97
- -
0.25
- -
- -
Revenue per Share
-1.16
8.6
-21.44
-0.97
-0.29
- -
Basic EPS, GAAP
0.61
-3.87
-0.67
-5.16
-1.62
-0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.77
6.83
-14.61
-14.78
-9.39
-9.39
Book Value per Share
-0.71
12.39
-8.53
-1.84
0.01
0.01
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
Sales/Revenue/Turnover
-11.98
43.05
- -
-387.72
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
19.51
- -
- -
- -
- -
Effective Tax Rate (%)
-22.12
33.11
- -
-387.72
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
102.09
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
2
2
2

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-100.82%
Free Cash Flow
- -
- -
-56.66%
Net Income, GAAP
- -
- -
-59.25%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.29
-0.83
-0.05
- -
-0.97
2025
- -
- -
-0.39
- -
-0.29
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
CannAmerica Brands Corp. (CNNXF)
Nanologica AB (publ) (NICA.ST)
Interpharm Holdings, Inc. (IPAH)
Grand Pharmaceutical Group Limited (0512.HK)
Welcia Holdings Co., Ltd. (WLCGF)
Sandu Pharmaceuticals Limited (SANDUPHQ.BO)
Business
Rest Ez Inc. (RTEZ) develops, produces, and distributes sleep aid supplements in the United States. The company offers Rest EZ, a liquid soft gel capsule sleep aid formulated with all-natural ingredients including L-Theanine, Melatonin, and Valerian root; it markets this product through wholesalers, retailers, and direct online sales via www.restez.net. Rest Ez Inc. operates primarily in the personal care products industry, targeting consumers seeking natural sleep solutions. Founded in 2016 by Brandon Sosa and headquartered in the United States with a corporate office at 1398 W. Mason, the company maintains its fiscal year-end on March 31. No major acquisitions, funding rounds, partnerships, or strategic shifts have been reported for Rest Ez Inc. in the last two years.